Nothing Special   »   [go: up one dir, main page]

GB202402048D0 - Therapeutic antibodies - Google Patents

Therapeutic antibodies

Info

Publication number
GB202402048D0
GB202402048D0 GBGB2402048.9A GB202402048A GB202402048D0 GB 202402048 D0 GB202402048 D0 GB 202402048D0 GB 202402048 A GB202402048 A GB 202402048A GB 202402048 D0 GB202402048 D0 GB 202402048D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic antibodies
antibodies
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2402048.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GBGB2402048.9A priority Critical patent/GB202402048D0/en
Publication of GB202402048D0 publication Critical patent/GB202402048D0/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
GBGB2402048.9A 2024-02-14 2024-02-14 Therapeutic antibodies Pending GB202402048D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2402048.9A GB202402048D0 (en) 2024-02-14 2024-02-14 Therapeutic antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2402048.9A GB202402048D0 (en) 2024-02-14 2024-02-14 Therapeutic antibodies

Publications (1)

Publication Number Publication Date
GB202402048D0 true GB202402048D0 (en) 2024-03-27

Family

ID=90354556

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2402048.9A Pending GB202402048D0 (en) 2024-02-14 2024-02-14 Therapeutic antibodies

Country Status (1)

Country Link
GB (1) GB202402048D0 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040043401A1 (en) 2002-05-28 2004-03-04 Sloan Kettering Institute For Cancer Research Chimeric T cell receotors
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2019200007A1 (en) 2018-04-10 2019-10-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
WO2021108613A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2021113679A1 (en) 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040043401A1 (en) 2002-05-28 2004-03-04 Sloan Kettering Institute For Cancer Research Chimeric T cell receotors
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2019200007A1 (en) 2018-04-10 2019-10-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
WO2021108613A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2021113679A1 (en) 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. BAG36664.1
"Uniprot", Database accession no. Q7Z7D3-1
A. L. SMITH ET AL., J. MED. CHEM., vol. 39, no. 11, 1996, pages 2103 - 2117
AGNEW, CHEM INTL. ED. ENGL, vol. 33, 1994, pages 183 - 186
ALLEY, CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 14, 2010, pages 1 - 9
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 405 - 410
ATWELL ET AL.: "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library", J. MOL. BIOL., vol. 270, 1997, pages 26 - 35, XP002610109, DOI: 10.1006/jmbi.1997.1116
BRINKMANNKONTERMANN: "The making of bispecific antibodies", MABS, vol. 9, no. 2, 2017, pages 182 - 212
CHOI IH ET AL.: "Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family", J IMMUNOL., vol. 171, 2003, pages 4650 - 4, XP002493422
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
D. BOGER, PURE & APPL. CHEM., vol. 66, no. 4, 1994, pages 837 - 844
DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123
FRENAY ET AL., INT. J. MOL. SCI., vol. 23, no. 23, 2022, pages 14918
GITTO ET AL., CANCER RES, vol. 83, 2023, pages 1133
GREENSAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
GUNASEKARAN ET AL.: "Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG", J. BIOL. CHEM., vol. 285, 2010, pages 19637 - 19646, XP055546816, DOI: 10.1074/jbc.M110.117382
HA ET AL.: "Frontiers in Immunology Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications", THERAPEUTIC ANTIBODIES AND PROTEINS, vol. 7, 2016
I. BHATNAGARET, MAR. DRUGS, vol. 8, 2010, pages 2702 - 2720
J.B. RIDGWAY ET AL.: "Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerisation", PROTEIN ENG., vol. 9, 1996, pages 617 - 621, XP002610995, DOI: 10.1093/protein/9.7.617
JOHNSON ET AL., ANTICANCER RES., vol. 15, 1995, pages 1387 - 93
KABAT ET AL., ANN. NY ACAD. SCI., vol. 190, 1971, pages 382 - 391
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NIH PUBLICATION
LAU ET AL., BIOORG-MED-CHEM, vol. 3, 1995, pages 1305 - 12
LAU ET AL., BIOORG-MED-CHEM., vol. 3, 1995, pages 1299 - 1304
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 29, 2005, pages 185 - 203
METRANGOLO ET AL., CANCERS, vol. 16, 2024, pages 447
MORETTI ET AL., BMC PROC, vol. 7, 2013
PEARSONLIPMAN, PNAS USA, 1988, pages 2444 - 2448
PIVOT ET AL., EUROPEAN ONCOLOGY, vol. 4, no. 2, 2008, pages 42 - 45
SADELAIN ET AL., CURR OPIN IMMUNOL, vol. 21, no. 2, 2009, pages 215 - 223
SENTER, CANCER J., vol. 14, no. 3, 2008, pages 154 - 169
SICA GL ET AL.: "B7-H4, a molecule of the B7 family, negatively regulates T cell immunity", IMMUNITY, vol. 18, 2003, pages 849 - 61, XP002485368, DOI: 10.1016/S1074-7613(03)00152-3
SMITHWATERMAN, J. MOL BIOL., vol. 147, 1981, pages 195 - 197
STERNER, R.C.STERNER, R.M: "CAR-T cell therapy: current limitations and potential strategies", BLOOD CANCER J., vol. 11, 2021, pages 69
T. L. SIMMONS ET AL., MOL. CANCER THER., vol. 4, no. 2, 2005, pages 333 - 342
WANG ET AL., ACTA PHARMACEUTICA SINICA B, vol. 13, no. 10, 2023, pages 4025 - 4059
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546

Similar Documents

Publication Publication Date Title
GB202012331D0 (en) Therapeutic antibodies
GB202402048D0 (en) Therapeutic antibodies
GB202402046D0 (en) Therapeutic antibodies
GB202401988D0 (en) Therapeutic antibodies
GB202311497D0 (en) Therapeutic antibodies
GB202310818D0 (en) Therapeutic antibodies
IL314314A (en) Therapeutic antibodies
GB202300904D0 (en) Therapeutic antibodies
GB202217993D0 (en) Therapeutic antibodies
GB202209454D0 (en) Therapeutic antibodies
GB202208544D0 (en) Therapeutic antibodies
GB202202990D0 (en) Therapeutic antibodies
GB202202635D0 (en) Therapeutic antibodies
GB202413525D0 (en) Antibodies
GB202411940D0 (en) Anti-CLEC12A Antibodies
GB202410983D0 (en) Antibodies
GB202410982D0 (en) Antibodies
GB202409026D0 (en) Antibodies
GB202405480D0 (en) Antibodies
GB202404343D0 (en) Antibodies
GB202404344D0 (en) Antibodies
GB202400941D0 (en) Antibodies
GB202108677D0 (en) Therapeutic antibodies
GB202406710D0 (en) Therapy
GB202405750D0 (en) Therapy